Item Type | Name |
Academic Article
|
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
|
Concept
|
Chromosomes, Human, Y
|
Concept
|
Chromosomes, Human, Pair 16
|
Concept
|
Chromosomes, Human, Pair 17
|
Concept
|
Chromosomes, Human
|
Concept
|
Chromosomes, Human, Pair 11
|
Concept
|
Chromosomes, Human, Pair 1
|
Concept
|
Chromosomes, Human, Pair 19
|
Concept
|
Chromosomes, Human, Pair 3
|
Concept
|
Chromosomes, Human, Pair 20
|
Concept
|
Chromosomes, Human, Pair 5
|
Concept
|
Chromosomes, Human, Pair 21
|
Concept
|
Chromosomes, Human, Pair 8
|
Concept
|
Chromosomes, Human, Pair 10
|
Concept
|
Chromosomes, Human, Pair 7
|
Concept
|
Chromosomes, Human, Pair 6
|
Concept
|
Chromosomes, Human, Pair 9
|
Concept
|
Chromosomes, Human, Pair 22
|
Academic Article
|
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
|
Academic Article
|
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.
|
Academic Article
|
Chromosomal abnormalities in chronic lymphocytic leukemia.
|
Academic Article
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Academic Article
|
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
|
Academic Article
|
Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
|
Academic Article
|
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.
|
Academic Article
|
Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.
|
Academic Article
|
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
|
Academic Article
|
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
|
Academic Article
|
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.
|
Academic Article
|
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
|
Academic Article
|
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
|
Academic Article
|
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
|
Academic Article
|
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
|
Academic Article
|
Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
|
Academic Article
|
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
|
Academic Article
|
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
|
Academic Article
|
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
|
Academic Article
|
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
|
Academic Article
|
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
|
Academic Article
|
Therapy with azanucleosides for myelodysplastic syndromes.
|
Academic Article
|
Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.
|
Academic Article
|
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
|
Academic Article
|
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.
|
Academic Article
|
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.
|
Academic Article
|
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.
|
Academic Article
|
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
|
Academic Article
|
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.
|
Academic Article
|
Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
|
Academic Article
|
Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
|
Academic Article
|
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
|
Academic Article
|
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
|
Academic Article
|
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
|
Academic Article
|
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
|
Academic Article
|
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
|
Academic Article
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
|
Academic Article
|
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
|
Academic Article
|
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
|
Academic Article
|
Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
|
Academic Article
|
Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy.
|
Academic Article
|
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
|
Academic Article
|
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment.
|